Skip to main content
. 2018 Jun 1;18:623. doi: 10.1186/s12885-018-4428-0

Fig. 2.

Fig. 2

Prognostic impact of the 22-node measure on CCS for patients aged < 40. a 5-year CSSs in all patients between lymph node count ≥22 and < 22; (b) 5-year CSSs in patients with stage I between lymph node count ≥22 and < 22; (c) 5-year CSSs in patients with stage II between lymph node count ≥22 and < 22; (d) 5-year CSSs in patients with stage III between lymph node count ≥22 and < 22